Gabriela N. Crespi

St. Vincent's Institute Of Medical Research
Fitzroy, VIC 3065, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Crystal structure of Alzheimer's disease phospholipase D3 provides a molecular basis for understanding its normal and pathological functions.

Crystal structure of Alzheimer's disease phospholipase D3 provides a molecular basis for understanding its normal and pathological functions.

Journal: The FEBS journal

Published: April 21, 2024

Correction: Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncted Abeta in sporadic Alzheimer disease cases and mouse models.

Correction: Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncted Abeta in sporadic Alzheimer disease cases and mouse models.

Journal: Acta neuropathologica

Published: March 25, 2024

Structural biology of cell surface receptors implicated in Alzheimer's disease.

Structural biology of cell surface receptors implicated in Alzheimer's disease.

Journal: Biophysical reviews

Published: September 03, 2021

Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes Aβ Phagocytosis.

Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes Aβ Phagocytosis.

Journal: iScience

Published: September 08, 2018

Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway.

Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway.

Journal: Molecular neurodegeneration

Published: July 29, 2016

Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.

Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.

Journal: Acta neuropathologica

Published: July 01, 2015

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.

Journal: Scientific reports

Published: December 03, 2014

Anti-Aβ antibody target engagement: a response to Siemers et al.

Anti-Aβ antibody target engagement: a response to Siemers et al.

Journal: Acta neuropathologica

Published: August 06, 2014

Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

Journal: Acta neuropathologica

Published: March 12, 2014

Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β.

Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β.

Journal: Acta crystallographica. Section F, Structural biology communications

Published: December 05, 2013

Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.

Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.

Journal: Scientific reports

Published: November 13, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026